GNOM - ETF AI Analysis
Top Page
Global X Genomics & Biotechnology ETF (GNOM)
Rating:62Neutral
Price Target:―
Positive Factors
Strong Year-To-Date Performance
The ETF has delivered positive returns so far this year, showing that its strategy has recently been working for investors.
Leading Winners Among Top Holdings
Several major positions, including Moderna and BioNTech, have shown strong gains this year, helping support the fund’s overall results.
Focused Exposure to Genomics and Biotechnology
The fund is heavily invested in health care and genomics-related companies, giving investors targeted access to a specialized growth area.
Negative Factors
High Sector Concentration
Almost all assets are in the health care sector, which increases the risk if biotechnology and genomics stocks fall out of favor.
Mixed Performance Among Top Holdings
Several key holdings such as Guardant Health, Natera, and BioMarin have shown weak performance this year, which can drag on the ETF’s returns.
Relatively High Expense Ratio
The fund’s fees are on the higher side for an ETF, which means more of the investment return goes toward costs rather than to investors.
GNOM vs. SPDR S&P 500 ETF (SPY)
AUM50.90M
RegionGlobal
Expense Ratio0.50%
Beta1.18
IssuerGlobal X
Inception DateApr 05, 2019
Dividend Yield1.37%
Asset ClassEquity
Index TrackedSolactive Genomics Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume4,945
30 Day Avg. Volume8,273
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
64.79Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering49
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
GNOM Summary
GNOM is the Global X Genomics & Biotechnology ETF, which follows the Solactive Genomics Index and focuses on companies using DNA and gene science to develop new medical treatments and tests. Most of its holdings are U.S. health care firms working on gene editing, sequencing, and personalized medicine. Well-known names in the fund include Moderna and Illumina. Someone might invest in GNOM if they want growth potential from cutting-edge biotech and a basket of different genomics companies instead of picking single stocks. However, it is very focused on one high-risk sector, so its price can swing a lot and may drop sharply.
How much will it cost me?The Global X Genomics & Biotechnology ETF (GNOM) has an expense ratio of 0.50%, meaning you’ll pay $5 per year for every $1,000 invested. This is higher than average because it is actively managed to focus on a specialized sector like genomics and biotechnology, which requires more research and expertise. It’s designed to give investors exposure to cutting-edge companies in this innovative field.
What would affect this ETF?The GNOM ETF, focused on genomics and biotechnology, could benefit from advancements in gene editing and personalized medicine, as well as increased global healthcare spending and innovation. However, it may face challenges from regulatory hurdles, high research costs, and potential market volatility in the healthcare sector. Its global exposure and top holdings in cutting-edge companies position it well for growth but also make it sensitive to changes in economic conditions and industry-specific risks.
GNOM Top 10 Holdings
GNOM is a pure play on global genomics, with nearly all its weight in health care names pushing the frontiers of gene editing, sequencing, and precision medicine. Moderna and BioNTech are doing much of the heavy lifting lately, with their shares rising again as investors warm to post-vaccine pipelines. Smaller biotech names like Praxis and Arrowhead are also climbing, adding extra fuel but with more bumpiness. On the flip side, Illumina, Guardant Health, and Natera have shown mixed to lagging trends, occasionally putting a brake on the fund’s momentum.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Moderna | 8.06% | $4.16M | $20.12B | 77.35% | 59 Neutral | |
| Arrowhead Pharmaceuticals | 7.20% | $3.71M | $10.35B | 444.38% | 57 Neutral | |
| Praxis Precision Medicines | 6.91% | $3.57M | $9.60B | 809.06% | 58 Neutral | |
| Illumina | 5.28% | $2.73M | $19.43B | 66.43% | 71 Outperform | |
| Guardant Health | 4.83% | $2.49M | $11.66B | 84.41% | 61 Neutral | |
| Natera | 4.15% | $2.14M | $28.88B | 33.60% | 73 Outperform | |
| Vertex Pharmaceuticals | 4.05% | $2.09M | $109.45B | -14.20% | 78 Outperform | |
| BioMarin Pharmaceutical | 4.02% | $2.08M | $10.23B | -14.57% | 75 Outperform | |
| BioNTech SE | 4.00% | $2.07M | $26.50B | -1.86% | 53 Neutral | |
| Bio-Techne | 3.43% | $1.77M | $8.48B | 9.67% | 64 Neutral |
GNOM Technical Analysis
Positive
―
Price Trends
45.10
Positive
46.09
Positive
42.73
Positive
Market Momentum
0.21
Positive
54.88
Neutral
48.34
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For GNOM, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 45.76, equal to the 50-day MA of 45.10, and equal to the 200-day MA of 42.73, indicating a bullish trend. The MACD of 0.21 indicates Positive momentum. The RSI at 54.88 is Neutral, neither overbought nor oversold. The STOCH value of 48.34 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GNOM.
GNOM Peer Comparison
Comparison Results
Performance Comparison
GNOM
Global X Genomics & Biotechnology ETF
46.31
16.56
55.66%
FFND
Future Fund Active ETF
―
―
―
EVX
VanEck Environmental Services ETF
―
―
―
CSNR
Cohen & Steers Natural Resources Active ETF
―
―
―
SOCL
Global X Social Media ETF
―
―
―
HELX
Franklin Genomic Advancements ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents